

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 August 2024 (02.08.2024)



(10) International Publication Number
WO 2024/156908 A1

(51) International Patent Classification:
A61K 9/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2024/051996

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
26 January 2024 (26.01.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23153562.6 26 January 2023 (26.01.2023) EP
23155924.6 09 February 2023 (09.02.2023) EP

(71) Applicant: **AC IMMUNE SA** [CH/CH]; EPFL Innovation Park, Building B, 1015 Lausanne (CH).

(72) Inventors: **DI BONAVENTURA, Ivan**; c/o AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH). **AYER, Maxime**; c/o AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne (CH).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury Square House, 8 Salisbury Square, London EC4Y 8AP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: LIPOSOMAL CONSTRUCT

(57) Abstract: A liposomal construct comprises a liposome, at least one adjuvant; and a peptide containing at least one T-cell epitope which comprises, consists essentially of, or consists of the amino acid sequence of SEQ ID NO: 4 or an analogue thereof that retains alanine at position 2 and does not contain any methionine residues. The peptide preferably has the amino acid sequence of SEQ ID NO: 6. The liposomal construct may be used to generate a liposomal vaccine composition that additionally comprises at least one antigenic peptide displayed on the surface of the liposome. The liposomal vaccine compositions are useful in therapy. Methods of manufacture are also described.



WO 2024/156908 A1